Hongdo Do

3.8k total citations
42 papers, 2.2k citations indexed

About

Hongdo Do is a scholar working on Molecular Biology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Hongdo Do has authored 42 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 19 papers in Cancer Research and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Hongdo Do's work include Cancer Genomics and Diagnostics (18 papers), Lung Cancer Treatments and Mutations (14 papers) and Molecular Biology Techniques and Applications (9 papers). Hongdo Do is often cited by papers focused on Cancer Genomics and Diagnostics (18 papers), Lung Cancer Treatments and Mutations (14 papers) and Molecular Biology Techniques and Applications (9 papers). Hongdo Do collaborates with scholars based in Australia, United States and Germany. Hongdo Do's co-authors include Alexander Dobrovic, Stephen B. Fox, Paul Mitchell, Stephen Q. Wong, Jason Li, Thomas John, Thomas Mikeska, Christoph Bock, Grant A. McArthur and Paul Mitchell and has published in prestigious journals such as Journal of Clinical Oncology, Analytical Chemistry and Cancer Research.

In The Last Decade

Hongdo Do

42 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hongdo Do Australia 22 1.2k 864 749 702 328 42 2.2k
Aaron R. Thorner United States 26 1.1k 0.9× 524 0.6× 694 0.9× 582 0.8× 251 0.8× 55 2.2k
Florence Le Calvez‐Kelm France 25 1.3k 1.1× 820 0.9× 783 1.0× 453 0.6× 190 0.6× 68 2.4k
Woonbok Chung United States 22 1.9k 1.6× 502 0.6× 846 1.1× 431 0.6× 418 1.3× 37 2.7k
Kerstin Haase Germany 11 1.1k 0.9× 1.1k 1.2× 544 0.7× 335 0.5× 255 0.8× 20 2.0k
Stanislav Volik Canada 20 1.1k 0.9× 976 1.1× 386 0.5× 927 1.3× 152 0.5× 33 2.1k
Rajiv Raja United States 24 930 0.8× 758 0.9× 989 1.3× 551 0.8× 337 1.0× 59 2.3k
Jharna Miya United States 10 727 0.6× 701 0.8× 830 1.1× 549 0.8× 486 1.5× 15 1.8k
Suk Hang Cheng Hong Kong 28 1.9k 1.6× 2.0k 2.4× 749 1.0× 447 0.6× 376 1.1× 49 3.1k
Tobias Grob Germany 25 992 0.8× 396 0.5× 954 1.3× 378 0.5× 122 0.4× 55 2.2k
Yuesheng Jin Sweden 30 1.1k 0.9× 604 0.7× 826 1.1× 340 0.5× 339 1.0× 59 2.3k

Countries citing papers authored by Hongdo Do

Since Specialization
Citations

This map shows the geographic impact of Hongdo Do's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hongdo Do with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hongdo Do more than expected).

Fields of papers citing papers by Hongdo Do

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hongdo Do. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hongdo Do. The network helps show where Hongdo Do may publish in the future.

Co-authorship network of co-authors of Hongdo Do

This figure shows the co-authorship network connecting the top 25 collaborators of Hongdo Do. A scholar is included among the top collaborators of Hongdo Do based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hongdo Do. Hongdo Do is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Leal, José Luis, Marcin Szaumkessel, Trishe Leong, et al.. (2020). NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer. Lung Cancer. 146. 154–159. 24 indexed citations
2.
Arulananda, Surein, Hongdo Do, Gareth Rivalland, et al.. (2019). Standard dose osimertinib for erlotinib refractory T790M-negative EGFR-mutant non-small cell lung cancer with leptomeningeal disease. Journal of Thoracic Disease. 11(5). 1756–1764. 10 indexed citations
3.
Cameron, Daniel, Jan Schröder, Jocelyn Sietsma Penington, et al.. (2017). GRIDSS: sensitive and specific genomic rearrangement detection using positional de Bruijn graph assembly. Genome Research. 27(12). 2050–2060. 182 indexed citations
4.
Arulananda, Surein, Hongdo Do, Ashan Musafer, et al.. (2017). Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 12(11). 1728–1732. 137 indexed citations
5.
Thai, Alesha, Puey Ling Chia, Prudence A. Russell, et al.. (2017). De novo activating epidermal growth factor mutations (EGFR) in small‐cell lung cancer. Internal Medicine Journal. 47(9). 1071–1074. 3 indexed citations
6.
Goh, Su Kah, et al.. (2016). Donor-specific cell-free DNA as a non-invasive marker of organ rejection after liver transplantation: A pilot study. Transplantation. 100(7). 2 indexed citations
7.
Do, Hongdo, Daniel Cameron, Ramyar Molania, et al.. (2016). Digital PCR of Genomic Rearrangements for Monitoring Circulating Tumour DNA. Advances in experimental medicine and biology. 924. 139–146. 5 indexed citations
8.
Wong, Stephen Q., Jason Li, Angela Tan, et al.. (2014). Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. BMC Medical Genomics. 7(1). 23–23. 192 indexed citations
9.
Lim, Annette M., Ida Candiloro, Nicholas C. Wong, et al.. (2014). Quantitative methodology is critical for assessing DNA methylation and impacts on correlation with patient outcome. Clinical Epigenetics. 6(1). 22–22. 20 indexed citations
10.
Do, Hongdo, Nicholas C. Wong, Carmel Murone, et al.. (2014). A critical re-assessment of DNA repair gene promoter methylation in non-small cell lung carcinoma. Scientific Reports. 4(1). 4186–4186. 38 indexed citations
11.
Young, Richard J., Kelly Waldeck, Claire Martin, et al.. (2014). Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. Pigment Cell & Melanoma Research. 27(4). 590–600. 154 indexed citations
12.
Clay, Timothy, Hongdo Do, Vijaya Sundararajan, et al.. (2014). The Clinical Relevance of Pathologic Subtypes in Metastatic Lung Adenocarcinoma. Journal of Thoracic Oncology. 9(5). 654–663. 21 indexed citations
13.
Richter, Anna, Fabienne Grieu, Amerigo Carrello, et al.. (2013). A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma. Scientific Reports. 3(1). 1659–1659. 33 indexed citations
14.
Anaka, Matthew, Christopher Hudson, Hongdo Do, et al.. (2013). Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors. BMC Medical Genomics. 6(1). 40–40. 27 indexed citations
15.
Wong, Stephen Q., Jason Li, Renato Salemi, et al.. (2013). Targeted-capture massively-parallel sequencing enables robust detection of clinically informative mutations from formalin-fixed tumours. Scientific Reports. 3(1). 3494–3494. 39 indexed citations
16.
Do, Hongdo, Stephen Q. Wong, Jason Li, & Alexander Dobrovic. (2013). Abstract 54: Marked reduction of sequence artifacts in massively parallel sequencing of formalin-fixed paraffin-embedded DNA by depletion of uracil containing templates.. Cancer Research. 73(8_Supplement). 54–54. 1 indexed citations
17.
Andrews, Miles C., Andreas Behren, Fiona Chionh, et al.. (2013). BRAF Inhibitor–Driven Tumor Proliferation in a KRAS-Mutated Colon Carcinoma Is Not Overcome by MEK1/2 Inhibition. Journal of Clinical Oncology. 31(35). e448–e451. 44 indexed citations
18.
Newnham, Genni M, Matthew Conron, Sue‐Anne McLachlan, et al.. (2011). Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer. BMC Cancer. 11(1). 93–93. 15 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aaron R. Thorner Breakdown of academic impact, for papers by Florence Le Calvez‐Kelm Breakdown of academic impact, for papers by Woonbok Chung Breakdown of academic impact, for papers by Kerstin Haase Breakdown of academic impact, for papers by Stanislav Volik Breakdown of academic impact, for papers by Rajiv Raja Breakdown of academic impact, for papers by Jharna Miya Breakdown of academic impact, for papers by Suk Hang Cheng Breakdown of academic impact, for papers by Tobias Grob Breakdown of academic impact, for papers by Yuesheng Jin
Rankless by CCL
2026